Ingredient Analysis Using CytoSolve® In Silico Systems Architecture to Quantify Relaxation Bioactives for Harm Reduction Research Innovation and Ingredient Optimization

Partner Description

British American Tobacco
British American Tobacco (BAT) is a global organization with advanced research and development capabilities focused on understanding biological mechanisms relevant to consumer products and harm-reduction science. BAT’s R&D group applies rigorous analytical, biological, and computational methods to study complex physiological systems, supporting evidence-based innovation and scientific transparency.

Challenge

BAT required a rigorous ingredient-focused scientific framework to understand how multiple bioactive ingredients individually and collectively influence biological systems associated with relaxation and stress modulation. These systems involve interconnected molecular networks spanning neurotransmitter signaling, hormonal regulation, immune responses, and neuromodulatory feedback loops.

Traditional experimental approaches are limited in their ability to isolate ingredient-specific contributions, characterize non-linear ingredient interactions, and evaluate combination effects across multiple pathways efficiently. BAT needed a scalable, quantitative approach capable of prioritizing ingredients, comparing combinations, and generating mechanistic insight without reliance on extensive in vitro or in vivo testing.

How CytoSolve® Enables Ingredient Analysis

CytoSolve applied its distributed computational systems biology platform to perform ingredient analysis and in silico combination screening grounded entirely in peer-reviewed scientific literature.

Six molecular systems central to relaxation biology were identified and modeled as ingredient-responsive pathways:

  • Gut microbiome–neuroinflammation signaling
  • Hypothalamic–pituitary–adrenal (HPA) axis signaling
  • Brain-derived neurotrophic factor (BDNF) signaling
  • Neurotransmitter pathways involving GABA and serotonin
  • Catecholamine signaling via dopamine
  • Endocannabinoid signaling centered on anandamide (AEA)
Each pathway was independently translated into a validated mathematical model using ordinary differential equations and encoded in SBML format. These models were dynamically integrated into a unified systems architecture, enabling ingredient-level interrogation while preserving pathway-specific biology.

Six shortlisted bioactive ingredients were computationally simulated across physiologically relevant dose ranges. The in silico ingredient analysis quantified how each ingredient influenced key biomarkers related to inflammation, cortisol dynamics, neurotransmission, and neurotrophic signaling, both independently and in combination. This approach enabled direct comparison of ingredient contributions and identification of complementary or synergistic effects relevant to formulation design.

Key Benefits Realized

  • Ingredient-level quantification of biological effects across interconnected relaxation pathways
  • Clear mechanistic attribution linking individual ingredients to molecular and physiological outcomes
  • Scalable in silico screening of multiple ingredients and combinations
  • Ingredient-informed framework supporting rational formulation optimization
  • Reduced dependence on early-stage animal and cell-based experimentation

Outcome

The CytoSolve® Systems Architecture delivered a comprehensive ingredient analysis of bioactive compounds influencing molecular systems underlying relaxation for British American Tobacco. By integrating multiple pathways into a single computational framework, the collaboration enabled data-driven ingredient prioritization, comparison, and combination strategy development. This case study demonstrates how ingredient-focused in silico systems modeling supports ethical, efficient, and mechanistically grounded innovation within modern harm-reduction and research-driven product development programs.